Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : ARS Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
ARS Inks Co-Promotion Deal with ALK-Abelló to Expand Reach of Neffy Nasal Spray
Details : Under the agreement, ARS will expand the approved product Neffy (epinephrine) by parterning with ALK-Abelló. It is being indicated for the treatment of Type I allergic reactions including anaphylaxis.
Product Name : Neffy
Product Type : Hormone
Upfront Cash : Undisclosed
May 02, 2025
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : ARS Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : 12 SQ-Bet Betula Verrucosa
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ITULAZAX® Tree Pollen Tablet Approved for Treatment of Children in Europe
Details : Itulazax (tree pollen sublingual allergy immunotherapy tablet) for treatment of young children and adolescents aged five to 17 has been approved by the health authorities in 17 EU countries.
Product Name : Itulazax
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 23, 2025
Lead Product(s) : 12 SQ-Bet Betula Verrucosa
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
